Hira Imad Cheema

Sourced from institutional research profiles (UAMS TRI or ARA).

Researcher

UAMS

Also affiliated: The University of Texas of the Permian Basin (2017); Texas Tech University (2017); The University of Texas MD Anderson Cancer Center (2017); Baptist Health Foundation (2022–2023); Winthrop Rockefeller Foundation (2024–2025); Texas Tech University Health Sciences Center (2017)

Faculty Researcher

5 h-index 19 pubs 296 cited

Research Areas

Biomedical Subjects

Links

ORCID Research Group UAMS TRI Profile

Edit your profile

OverviewAI-generated summary

Hira Imad Cheema's research focuses on gastrointestinal conditions and hematologic malignancies. Recent publications address the endoscopic management of gastric neoplasms, the diagnosis of duodenal lesions, and the management of Heyde's syndrome. In hematology, Cheema has investigated T cell-redirecting therapy for relapsed multiple myeloma, examining the prognostic impact of lymphocyte counts and immune composition in bispecific antibody therapy, as well as cytomegalovirus reactivation in patients treated with teclistamab. Additionally, Cheema has contributed to research on the potential hepatic effects of methotrexate, concluding that existing evidence does not support a link between the drug and liver fibrosis. Further work includes evaluating stress testing for coronary artery disease in liver transplant candidates. Cheema collaborates with researchers at the University of Arkansas for Medical Sciences, including Ramya Bachu and Tanvi H Patel.

Metrics

h-index: 5
Publications: 19
Citations: 296

Selected Publications

The prognostic impact of lymphocyte counts and immune composition in bispecific antibody therapy in relapsed/refractory multiple myeloma (2026)

Research Square DOI OpenAlex
In vivo CAR T-cell engineering in B-cell malignancies: A systematic review of emerging clinical and translational evidence. (2026)

Journal of Clinical Oncology DOI OpenAlex
DLL3-targeted therapy with tarlatamab in small cell lung cancer across lines of therapy: A systematic review of prospective and randomized clinical trials. (2026)

Journal of Clinical Oncology DOI OpenAlex
Real-world infectious complications and IVIG utilization after teclistamab in relapsed/refractory multiple myeloma. (2026)

Journal of Clinical Oncology DOI OpenAlex
Influence of genomic and clinical high-risk features on outcomes after BCMA-directed bispecific antibody therapy in relapsed/refractory multiple myeloma. (2026)

Journal of Clinical Oncology DOI OpenAlex
Clinical outcomes and risk factors of cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients (2026)

Blood Cancer Journal DOI OpenAlex
Cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients: Clinical outcomes and risk factors (2025)

Blood DOI OpenAlex
Case Report: Teclistamab in the treatment of idiopathic immune thrombocytopenia in patients with multiple myeloma (2025)

Frontiers in Hematology 1 citation DOI OpenAlex
Minimal Residual Disease (MRD) Status and Its Impact on Clinical Outcome Is Highly Variable in Multiple Myeloma and Dependent on Molecular Subgroups Defined By Gene Expression Profiling (GEP) (2024)

Blood DOI OpenAlex
Exploring T cell subsets as predictors of response to BCMA targeting bispecific antibody therapy in multiple myeloma. (2024)

Journal of Clinical Oncology 2 citations DOI OpenAlex
A Single Center Experience of T Cell Redirecting Therapy Post Stem Cell Transplantation in Relapsed Multiple Myeloma (2024)

Transplantation and Cellular Therapy 1 citation DOI OpenAlex
Amyloid Light-Chain (AL) Amyloidosis of the Trachea Associated With an Indolent B-cell Neoplasm (2024)

Cureus DOI OpenAlex
A Case of Duodenal “Spot” Diagnosis (2022)

Cureus 2 citations DOI OpenAlex